In a report issued on November 19, Danielle Antalffy from Leerink Partners maintained a Buy rating on Johnson & Johnson (JNJ – Research Report), with a price target of $200.00. The company's shares closed last Tuesday at $155.93. According to TipRanks.com, Antalffy is a 4-star analyst with an average return of 11.9% and a 52.2% success rate. Antalffy covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Inspire Medical Systems, and Treace Medical Concepts. Currently, the analyst consensus on Johnson & Johnson is a Strong Buy with an average price target of $195.00, which is a 23.0% upside from current levels.
https://www.tipranks.com/news/blurbs/johnson-johnson-jnj-gets-a-buy-rating-from-leerink-partners?utm_source=advfn.com&utm_medium=referral